Immunoglobulin heavy- and light-chain in repertoire in splenic marginal lymphoma

Molecular Medicine

Volumn 10, Issue 7-12, 2004, Pages 89-95

  Stamatopoulos, Kostas ^a,d   Belessi, Chrysoula ^b   Papadaki, Theodora ^c   Kalagiakou, Evangelia ^b   Stavroyianni, Niki ^a   Douka, Vassiliki ^a   Afendaki, Stavroula ^c   Saloum, Riad ^a   Parasi, Alkaterini ^b   Anagnostou, Dimitra ^c   Laoutaris, Nikolaus ^b   Fassas, Athanasios ^a   Anagnostopoulos, Achilles ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; T LYMPHOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER STAGING; CLINICAL ARTICLE; CLONE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE REARRANGEMENT; GENE SEQUENCE; GENOTYPE; GERM LINE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MALE; MORPHOLOGY; PRIORITY JOURNAL; SOMATIC MUTATION; SPLENIC MARGINAL ZONE LYMPHOMA; TUMOR DIFFERENTIATION;

COMPLEMENTARITY DETERMINING REGIONS; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN; HUMANS; IMMUNOGENETICS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; LYMPHOMA; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; SPLENIC NEOPLASMS;

EID: 29244469945     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2005-00001.Stamatopoulos     Document Type: Article

References (55)

1. Zandvoort A, Timens W. (2002) The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general 1st-line defense against blood-borne antigens. Clin. Exp. Immunol. 130:4-11.
2. Lopes-Carvalho T, Kearney JF. (2004) Development and selection of marginal zone B cells, Immunol. Rev. 197:192-205.
3. Martin F, Kearney JF. (2002) Marginal-zone B cells. Nat. Rev. Immunol. 2: 323-35.
4. Dunn-Walters DK, Isaacson PG, Spencer J. (1996) Sequence analysis of rearranged IgVH genes from microdissected human Peyer's patch marginal zone B cells. Immunology 88:618-24.
5. Tierens A, Delabie J, Michiels L, Vandenberghe P, De Wolf-Peeters C. (1999) Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. Blood 93:226-34.
6. Dono M et al. (2000) Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J. Immunol. 164:5596-604.
7. Thieblemont C et al. (2003) Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 4:95-103.
8. Harris NL et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. 17: 3835-49.
9. Zhu D, Oscier DG, Stevenson FK. (1995) Splenic lymphoma with villaus lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes. Blood 85:1603-7.
10. Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG. (1998) Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. Hum. Pathol. 29:585-93.
11. Algara P et al. (2002) Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 99:1299-304.
12. Bahler DW, Pindzola JA, Swerdlow SH. (2002) Splenic marginal zone lymphomas appear to originate from different B cell types. Am. J. Pathol. 161:81-8.
13. Zhu D, Orchard J, Oscier DG, Wright DH, Stevenson FK. (2002) V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood 100:2659-61.
14. Tierens A et al. (2003) Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. Am. J. Pathol. 162:681-9.
15. Mateo MS et al. (2001) Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5′ non-coding region of the bcl-6 gene. Leukemia 15:628-34.
16. Sole F et al. (2001) Splenic marginal zone B-cell lymphomas: 2 cytogenetic subtypes, 1 with gain of 3q and the other with loss of 7q. Haematologica 86:71-7.
17. Hermine O et al. (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med. 347:89-94.
18. Vargas-Madrazo E, Lara-Ochoa F, Ramirez-Benites MC, Almagro JC. (1997) Evolution of the structural repertoire of the human V(H) and Vkappa germline genes. Int. Immunol. 9:1801-15.
19. Sahota SS, Leo R, Hamblin TJ, Stevenson FK. (1997) Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood. 89:219-26.
20. Stamatopoulos K et al. (1997) Follicular lymphoma immunoglobulin kappa light chains are affected by the antigen selection process, but to a lesser degree than their partner heavy chains. Br. J. Haematol. 96:132-46.
21. Marks J et al. (1991) By-passing immunization: Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-97.
22. Brauninger A, Goossens T, Rajewsky K, Kuppers R. (2001) Regulation of immunoglobulin light chain gene rearrangements during early B cell development in the human. Eur. J. Immunol. 31:3631-7.
23. Lefranc M-P, Lefranc G. (2001 ) The immunoglobulin FactsBook. Academic Press, London.
24. Lefranc M-P. (2003) IMGT databases, web resources and tools for immunoglobulin and T cell receptor sequence analysis, http://imgt.cines.fr. Leukemia 17:260-6.
25. Lefranc MP. (2001) Nomenclature of the human immunoglobulin heavy (IGH) genes. Exp. Clin. Immunogenet. 18:100-16.
26. Lefranc MP. (2001) Nomenclature of the human immunoglobulin kappa (IGK) genes. Exp. Clin. Immunogenet. 18:161-74.
27. Lefranc MP. (2001) Nomenclature of the human immunoglobulin lambda (IGL) genes. Exp. Clin. Immunogenet. 18:242-54.
28. Lossos IS, Tibshirani R, Narasimhan B, Levy R. (2000) The inference of antigen selection on Ig genes. J. Immunol. 165:5122-6.
29. Rosner K et al. (2001 ) Third complementarity-determining region of mutated VH immunoglobulin genes contains shorter V, D, J, P, and N components than non-mutated genes. Immunology 103:179-87.
30. Brezinschek HP, Foster SJ, Brezinschek RI, Dorner T, Domiati-Saad R, Lipsky PE. (1997) Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+B cells. J. Clin. Invest. 99:2488-501.
31. Ruiz M, Pallares N, Contet V, Barbi V, Lefranc MP. (1999) The human immunogloburm heavy diversity (IGHD) and joining (IGHJ) segments. Exp. Clin. Immunogenet. 16:173-84.
32. Corbett SJ, Tomlinson IM, Sonnhammer EL, Buck D, Winter G. (1997) Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination. J. Mol. Biol. 270:587-97.
33. Foster SJ, Brezinschek HP, Brezinschek RI, Lipsky PE. (1997) Molecular mechanisms and selective influences that shape the kappa gene repertoire of IgM + B cells. J. Clin. Invest. 99:1614-27.
34. Ignatovich O, Tomlinson IM, Jones PT, Winter G. (1997) The creation of diversity in the human immunoglobulin V(lambda) repertoire. J. Mol. Biol. 268:69-77.
35. Ignatovich O, Tomlinson IM, Popov AV, Bruggemann M, Winter G. (1999) Dominance of intrinsic genetic factors in shaping the human immunoglobulin Vlambda repertoire. J. Mol. Biol. 294:457-65.
36. Vasicek TJ, Leder P. ( 1990) Structure and expression of the human immunoglobulin lambda genes. J. Exp. Med. 172:609-20.
37. Dorner T, Foster SJ, Brezinschek HP, Lipsky PE. (1998) Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements, Immunol. Rev. 162:161-71.
38. Belessi C, Stamatopoulos K, Stavroyianni N, Zoi K, Papadaki T, Kosmas C. (2001) Somatic hypermutation targeting to intrinsic hatspots of immunoglobulin genes in follicular lymphoma and multiple myeloma. Leukemia 15:1772-8.
39. Pommie C, Levadoux S, Sabatier R, Lefranc G, Lefranc MP. (2004) IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. J. Mol. Recognit. 17:17-32.
40. Brezinschek HP, Foster SJ, Dorner T, Brezinschek RI, Lipsky PE. (1998) Pairing of variable heavy and variable kappa chains in individual naive and memory B cells. J. Immunol. 160:4762-7.
41. de Wildt RM, Hoet RM, van Venrooij WJ, Tomlinson IM, Winter G. (1999) Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J. Mol. Biol. 285:895-901.
42. Stewart AK, Huang C, Long AA, Stollar BD, Schwartz RS. (1992) VH-gene representation in autoantibodies reflects the normal human B-cell repertoire, Immunol. Rev. 128:101-22.
43. Rao SP, Riggs JM, Friedman DF, Scully MS, LeBien TW, Silberstein LE. (1999) Biased VH gene usage in early lineage human B cells: evidence for preferential Ig gene rearrangement in the absence of selection. J. Immunol. 163:2732-40.
44. Yu K, Taghva A, Lieber MR. (2002) The cleavage efficiency of the human immunoglobulin heavy chain VH elements by the RAG complex: implications for the immune repertoire. J. Biol. Chem. 277:5040-6.
45. Chiorazzi N, Ferrarini M. (2003) B-cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21: 841-94.
46. Tobin G et al. (2003) Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 101:4952-7.
47. Ghia P et al. (2004) Geographical patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood First Edition Paper, prepublished online October 5, 2004: DOI 10.1182/blood-2004-07-2606.
48. Damle RN et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-7.
49. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-54.
50. Forconi F, Sahota SS, Lauria F, Stevenson FK. (2004) Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? Leukemia 18:882-3.
51. Barbas SM et al. (1995) Human autoantibody recognition of DNA. Proc. Natl. Acad. Sci. U.S.A. 92:2529-33.
52. Dono M et al. (2003) The human marginal zone B cell. Ann. N.Y. Acad. Sci. 987:117-24.
53. Pillai S, Cariappa A, Moran ST. (2004) Positive selection and lineage commitment during peripheral B-lymphocyte development, Immunol. Rev. 97: 206-18.
54. William J, Euler C, Christensen S, Shlomchik MJ. (2002) Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 297:2066-70.
55. Song H, Cerny J. (2003) Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen. J. Exp. Med. 198:1923-35.